authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release Since the FDA approval of pegcetacoplan in
The FDA has approved Apellis Pharmaceuticals' Syfovree (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to AMD.
The review team recommends approval of pegcetacoplan (Empaveli) for the treatment of adult patients with PNH. FDA-approved pharmacological therapies.
The U.S. Food and Drug Administration (FDA) has approved pegcetacoplan to treat paroxysmal nocturnal hemoglobinuria (PNH).
by MK Nielsen Cited by 3The FDA, USA approved SYFOVRE (pegcetacoplan injection) on The FDA, USA approved Izervay (avacincaptad pegol intravitreal
pegcetacoplan Treatment of autoimmune hemolytic anemia Designated Not FDA Approved for Orphan Indication.
The FDA has approved Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan approval of this medicine would be a
The FDA has approved pegcetacoplan (Empaveli) for the treatment of adults with eculizumab (Soliris) and ravulizumab (Ultomiris).
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!
Do you realize the world doesn't end at USA borders?